European Pharmaceutical Review

MARCH 1, 2024

Although pharma companies are working steadily to leverage the power of data and become more agile and resilient, there is still room for improvement. The post 2024 Pharmaceutical industry trends – discover the latest pharma quality and manufacturing trends appeared first on European Pharmaceutical Review.

Manufacturing 90

Manufacturing Pharma Pharmaceutical 90

Pharma Marketing Network

DECEMBER 6, 2023

Reuters Events: Pharma USA 2024 is where senior pharma executives from Commercial, Marketing, Medical Affairs, RWE, Market Access, Patient Engagement, as well as key stakeholders, will come together to map out how they can deliver value to overcome the challenges that are hindering scientific innovation. 

Pharma 52

Pharma Networking Marketing Medicine 52

Fierce Pharma

DECEMBER 22, 2023

And it is with cautious optimism that industry watchers see the trend continuing in 2024. . | Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.

Biopharma 331

Biopharma 331

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024.

Pharma 84

Pharma Government Medicine Marketing 84

MedCity News

FEBRUARY 14, 2024

2024 presents an exciting yet challenging landscape for global pharma marketers.

Marketing 110

Marketing Pharma Pharmaceutical Patients 110

Fierce Pharma

JANUARY 23, 2024

Ahead of key Stelara patent cliff, J&J's pharma business churns out growth fkansteiner Tue, 01/23/2024 - 11:32

Pharma 197

Pharma 197

Fierce Pharma

APRIL 4, 2024

Fierce Pharma Asia—Eisai's subQ Leqembi delay; Legend and J&J's supply deal with Novartis; China's Ozempic biosimilar aliu Thu, 04/04/2024 - 16:14

Pharma 130

Pharma 130

Fierce Pharma

FEBRUARY 1, 2024

On both fronts, Sanofi expects to see dividends in 2024. . | As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial respiratory launch with partner AstraZeneca.

245

245

Fierce Pharma

APRIL 11, 2024

As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001.

Biopharma 306

Biopharma Pharma 306

Fierce Pharma

JANUARY 4, 2024

In 2024, CDMOs can advance their priorities on three fronts, a group of experts said during a recent Evaluate webinar on the state of the industry. Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields.

Biopharma 261

Biopharma Manufacturing 261

Impetus Digital

FEBRUARY 16, 2024

In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.

Pharma 101

Pharma Healthcare Provider Healthcare Healthcare 101

Fierce Pharma

JANUARY 3, 2024

Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales.

Sales 268

Sales Biopharma Leads Marketing 268

Fierce Pharma

JANUARY 5, 2024

The last few days of 2023 and the beginning of 2024 featured a flurry of dealmaking by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies | A flurry of deals were inked by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies.

Pharma 173

Pharma 173

Tribeca Knowledge

DECEMBER 12, 2023

In our pharma trends for 2024, we look at some critical market access challenges in key territories for industry, and how companies can best prepare for them over the coming year.

Marketing 52

Marketing Pharma Pharmaceutical 52

Fierce Pharma

SEPTEMBER 7, 2023

Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years.

Biopharma 313

Biopharma Pharma 313

European Pharmaceutical Review

AUGUST 15, 2023

CPHI, the global pharmaceutical event that spans the entire supply chain from ingredients and finished dosages to machinery, bio, and packaging will return to Fiera Milano (Rho) in 2024. We are delighted to be returning to Fiera Milano, as Italy and the Lombardy region are widely known as one of the key pharma manufacturing centres in Europe.

Manufacturing 94

Manufacturing Pharma Pharmaceutical Pharmaceutical research 94

European Pharmaceutical Review

APRIL 29, 2024

Articles included in Issue 2 of European Pharmaceutical Review – our cell and gene therapy focus – include: CELL & GENE THERAPY Proper planning prevents CMC disasters for cell and gene therapies Drew Hope, Ryan Guest and Clare Blue eXmoor Pharma SUPPLY CHAIN Fresh or frozen?

Pharmaceutical 52

Pharmaceutical Pharma 52

Fierce Pharma

JANUARY 3, 2024

When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit t | GSK has downgraded a licensing deal for Scynexis' antifungal ibrexafungerp following an ongoing recall of the drug's approved form, Brexafemme. (..)

Pharma 207

Pharma 207

Fierce Pharma

JANUARY 31, 2024

But the British pharma major says that the successful launch represents just one round of a boxing match, and much is still to be decided, especially with Moderna expected to join the battle in 2024. billion in sales in 2023 compared to $890 million for Pfizer's Abrysvo.

Pharma 298

Pharma Sales 298

PM360

JUNE 23, 2023

Press Release Contact: Kayla Walsh Awards Coordinator, PM360 646-300-8114 kayla.walsh@pm360online.com PM360 Now Accepting Entries for 2024 Pharma Choice Awards Call for the Best Healthcare Creative from the Past Year NEW YORK, NY, June 22, 2023 : The 2024 PM360 Pharma Choice Awards are officially open for entries.

Pharma 52

Pharma Marketing Healthcare Healthcare 52

European Pharmaceutical Review

MAY 25, 2023

CPHI’s Pharmapack Awards 2024 are open for submissions. The Pharmapack Awards 2024 (January 24-25 2024) will be held during the event’s opening day. In keeping with the wider trend in Pharma, the Exhibitor Innovation Awards will no longer include one dedicated sustainability category.

Distribution 76

Distribution Pharma Pharmaceutical Patients 76

Fierce Pharma

JANUARY 19, 2023

Bluebird extends cash runway to late 2024 with $113M raise through stock sale esagonowsky Thu, 01/19/2023 - 08:30

Sales 228

Sales 228

Pharma Marketing Network

DECEMBER 12, 2023

Upcoming Informa Connect Events: Speaker Programs Summit – February 26-28, 2024 Event Name: Rare Disease Summit – March 19-21, 2024 PAP – Patient Assistance & Access Programs – March 19-21, 2024 Hub and Specialty Pharmacy Models East – March 19-21, 2024 Pharma Forum – March 24-27, 2024 Pharmaceutical Compliance Congress (..)

Education 40

Education Networking Pharma Pharmaceutical 40

Fierce Pharma

DECEMBER 19, 2023

As the biopharma world readies for the turn of the calendar, the all-too-familiar topic of drug pricing once again presents an industry-wide overhang. Based on the series of measures centered on U.S. drug prices coming out of Washington, the Biden administration is clearly emboldened on the topic.

Biopharma 193

Biopharma Pharma 193

Fierce Pharma

JANUARY 9, 2023

JPM23: Bluebird touts gene therapy launch progress, extends cash runway to 2024. esagonowsky. Mon, 01/09/2023 - 09:26.

195

195

Pharmaceutical Technology

APRIL 16, 2024

The price ceiling policy has been in place for more than 20 years, but it has neither been very successful nor free of consequences for pharma companies.

Pharma 111

Pharma Marketing 111

Fierce Pharma

DECEMBER 12, 2023

The executive move comes amid a period of C-suite fluidity for Roche and its large pharma group. . | Genentech veteran Ashley Magargee, who was tapped to temporarily steer the Roche subsidiary in November, will don the mantle of full-time CEO on Jan.

Pharma 244

Pharma 244

PM360

FEBRUARY 22, 2024

Bronze Winner – EVERSANA INTOUCH and Mayne Pharma NEXTSTELLIS The NEXTSTELLIS campaign, It’s In Our Nature, champions women’s choice—created for women, directed by women—and empowers everyone who wants a choice in which estrogen to use in their birth control.

Pharma 52

Pharma Management 52

Pharmaceutical Technology

FEBRUARY 26, 2024

The upcoming Clinical Trial Supply Europe 2024 conference will round-up pharma and biotech delegates to discuss the trends and challenges in clinical trial supply industry.

Pharma 52

Pharma 52

Pharmaceutical Commerce

MARCH 20, 2024

In an interview with Pharma Commerce Associate Editor Don Tracy, Amy Niles, Chief Mission Officer, PAN Foundation offers her thoughts on the session and feedback from the audience at PAP 2024 in Philadelphia.

Patients 52

Patients Pharma 52

Pharmaceutical Commerce

APRIL 23, 2024

In an interview with Pharma Commerce Associate Editor Nicholas Saraceno, Will Robinson, Commercial Director, LogiPharma, talks themes of this year's event and future plans for the show.

Pharma 101

Pharma 101

Clarivate

APRIL 18, 2024

In 2024, watch as the global trendsetter brings to bear its technological expertise combined with a captive Prime membership, brand recognition, and national employer buy-in to re-envision healthcare that truly works around the patient. Healthcare segment) across the nation as part of a $1 billion cost-cutting strategy.

Retail 52

Retail Healthcare Healthcare Physicians 52

Eversana Intouch

NOVEMBER 20, 2023

As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors. Pharma/Biotech companies will continue to tailor their market access strategies locally to maximize patient outcomes and drive commercial value.

Marketing 83

Marketing Healthcare Healthcare Pharma 83

World of DTC Marketing

SEPTEMBER 6, 2021

SUMMARY: Those working in pharma know that ageism exists, especially in the sales force. Pharma has been purging older employees for some time, and when you reach the magic age of 50+, you’re going to be pushed to take “early retirement.” She hired an attorney and is now in litigation with the top 10 pharma companies.

Pharma 219

Pharma Sales Physicians Education 219

Fierce Pharma

APRIL 26, 2024

GSK pulls Pfizer and BioNTech into another vaccine patent lawsuit, this time surrounding the partners' mRNA-based COVID shots fkansteiner Fri, 04/26/2024 - 10:07

256

256

Fierce Pharma

SEPTEMBER 12, 2023

Xspray Pharma, before receiving an FDA slapdown in July, had expected to launch its competitor to Bristol Myers Squibb’s leukemia blockbuster Sprycel within the second half of 2023. 1, 2024, or potentially earlier under certain circumstances. 1, 2024, or potentially earlier under certain circumstances. 28, 2026.

FDA 268

FDA Pharma 268

Tribeca Knowledge

FEBRUARY 13, 2024

I n our latest report, Launch Readiness 2024 , we look at the prospects and obstacles facing new medicines in markets still recovering from the COVID-19 pandemic.

Prospecting 52

Prospecting Pharma Medicine Marketing 52